OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.25 +0.02 (+7.13%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock About CytoDyn Stock (OTCMKTS:CYDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytoDyn alerts:Sign Up Key Stats Today's Range$0.23▼$0.2550-Day Range$0.19▼$0.3652-Week Range$0.10▼$0.49Volume1.12 million shsAverage Volume3.45 million shsMarket Capitalization$303.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More… Remove Ads CytoDyn Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreCYDY MarketRank™: CytoDyn scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CytoDyn. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CytoDyn is -24.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytoDyn is -24.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CytoDyn's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.28% of the float of CytoDyn has been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in CytoDyn has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoDyn does not currently pay a dividend.Dividend GrowthCytoDyn does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.28% of the float of CytoDyn has been sold short.Short Interest Ratio / Days to CoverCytoDyn has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in CytoDyn has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.37 News SentimentCytoDyn has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CytoDyn this week, compared to 0 articles on an average week.Search InterestOnly 13 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoDyn insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of CytoDyn is held by insiders.Percentage Held by InstitutionsOnly 5.06% of the stock of CytoDyn is held by institutions.Read more about CytoDyn's insider trading history. Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Stock News HeadlinesCytoDyn Inc (296.SG)March 27, 2025 | finance.yahoo.comCytoDyn CEO writes March 2025 letter to shareholdersMarch 18, 2025 | markets.businessinsider.comElon Tax Shock?Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.April 1, 2025 | Altimetry (Ad)CytoDyn Inc.: March 2025 Letter to ShareholdersMarch 18, 2025 | finanznachrichten.deMarch 2025 Letter to ShareholdersMarch 18, 2025 | globenewswire.comCytoDyn announces survival observations in mTNBC patientsFebruary 25, 2025 | markets.businessinsider.comCytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | finanznachrichten.deMicro Cap Surging On Company Developed CCR5 Antagonist Showing Promise In PatientsFebruary 24, 2025 | msn.comSee More Headlines CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.1097 at the start of the year. Since then, CYDY stock has increased by 124.6% and is now trading at $0.2464. View the best growth stocks for 2025 here. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) released its earnings results on Tuesday, April, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.01. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings4/13/2021Today4/01/2025Next Earnings (Estimated)4/14/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,840,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-76.70% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual Sales$270,000.00 Price / Sales1,049.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-2.09Miscellaneous Outstanding Shares1,232,433,000Free Float1,224,197,000Market Cap$283.46 million OptionableNot Optionable Beta-0.28 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:CYDY) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.